Biotech RadarJobs updated

COMPANY

Salarius Pharmaceuticals

salariuspharma.com ↗ · Southwest

Clinical Phase 2

Profile checked Oct 10, 2026

Keywords: Ewing Sarcoma Myxoid Liposarcoma Desmoplastic Small Round Cell Tumor Extraskeletal Myxoid Chondrosarcoma Angiomatoid Fibrous Histiocytoma Clear Cell Sarcoma Myoepithelial Tumor Sclerosing Epithelioid Fibrosarcoma Lymphoma, Non-Hodgkin's, Adult Sarcoma,Soft Tissue Primary Pulmonary Myxoid Sarcoma Fibromyxoid Tumor Low Grade Fibromyxoid Sarcoma SP-3164 Seclidemstat SP-2577 Seclidemstat

$28.0MRaised (2 yrs)4Trials (company is sponsor)

Timeline

  1. Raise Private placement: $21M (up to, as announced), announced Jun 26, 2026. Source: SEC filing. source ↗
  2. Raise Follow-on offering: $7M (total, as published), announced Nov 11, 2025. Source: SEC filing. source ↗
  3. Trial start Early phase 1: Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma source ↗
  4. Trial start Phase 1/Phase 2: A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) source ↗
  5. Trial start 1: Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors source ↗
  6. Trial start Phase 1: Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas source ↗

Funding

Raised: $28.0M. Last 2 years.

Clinical trials (lead sponsor) 4

RecordTitlePhaseStatusStartPrimary completion
NCT05979857Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's LymphomaEarly phase 1Not yet recruitingMar 15, 2024Aug 15, 2025 (estimated)
NCT03600649Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related SarcomasPhase 1Unknown status (ClinicalTrials.gov)Jun 4, 20182025-09 (estimated)
NCT05266196A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)Phase 1/Phase 2Unknown status (ClinicalTrials.gov)Jan 15, 20222025-12 (estimated)
NCT03895684Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors1CompletedJun 25, 2019Apr 13, 2021 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback